Goldman Sachs Reiterates Buy Rating for Alignment Healthcare with $10.00 Price Target

August 12, 2023

🌥️Trending News

Alignment Healthcare ($NASDAQ:ALHC) is a healthcare services company that partners with providers, payors, and employers to deliver quality care, reduce costs, and improve outcomes. Nathan Rich, an analyst from Goldman Sachs, has reiterated his Buy rating for Alignment Healthcare, setting the price target at $10.00. The stock closed at $9.45 on Tuesday. His analysis is based on the company’s excellent progress as it continues to expand into new markets and partnerships.

In addition, Rich is optimistic about Alignment Healthcare’s plans for the future. He believes their investment in technology and data will help them remain competitive in the industry and allow them to continue to provide quality care at a lower cost. He also notes that the company is currently working on new services and products that could further drive growth in the near future. Overall, Rich remains bullish on Alignment Healthcare’s prospects and sees it as a good investment opportunity. He believes that the stock has potential for significant upside over the long-term and recommends investors consider adding it to their portfolios.

Share Price

The stock opened at $6.4 and closed at $6.5, representing a 0.9% increase from the previous closing price of $6.4. They also believe the company is well-positioned to capitalize on opportunities in the healthcare sector and recommend that investors buy in for the long haul. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Alignment Healthcare. More…

    Total Revenues Net Income Net Margin
    1.62k -163 -10.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Alignment Healthcare. More…

    Operations Investing Financing
    78.14 -152.87 16.75
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Alignment Healthcare. More…

    Total Assets Total Liabilities Book Value Per Share
    783.55 572.43 1.11
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Alignment Healthcare are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    23.7% -8.8%
    FCF Margin ROE ROA
    3.0% -41.3% -11.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale’s analysis of ALIGNMENT HEALTHCARE‘s financials shows that it is classified as a ‘cheetah’ on the Star Chart. This type of company is characterized by high revenue or earnings growth but with lower profitability and is generally considered to be less stable. As such, this may be an attractive prospect for investors who are looking for a higher risk investment with the potential for higher returns. The health score for ALIGNMENT HEALTHCARE is 6/10, indicating that it has intermediate health with regard to its cashflows and debt, and is likely to be able to pay off debt and fund future operations. Further, the company is strong in growth, medium in assets, and weak in dividends and profitability. This suggests that ALIGNMENT HEALTHCARE may be a good opportunity for investors who are looking for a higher risk investment with good potential rewards. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    Alignment Healthcare Inc and its competitors, Marpai Inc, Tabula Rasa HealthCare Inc, and CeCors Inc, are all healthcare companies that provide services and products related to health and wellness. All four companies are similar in that they offer similar products and services, but each company has its own unique selling points. Marpai Inc is a healthcare company that specializes in providing personalized care to its patients. Tabula Rasa HealthCare Inc is a healthcare company that focuses on providing evidence-based care to its patients. CeCors Inc is a healthcare company that specializes in providing care to its patients through a holistic approach.

    – Marpai Inc ($NASDAQ:MRAI)

    Marpai Inc is a publicly traded company with a market capitalization of $19.44 million as of 2022. The company has a negative return on equity of -64.66%, meaning that it has lost value for shareholders over the past year. Marpai Inc is a provider of online marketing and advertising services. The company offers a range of services including search engine optimization, pay-per-click management, and social media marketing.

    – Tabula Rasa HealthCare Inc ($NASDAQ:TRHC)

    Tabula Rasa HealthCare Inc is a healthcare technology company that provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. The company’s products and services include EHR-based clinical decision support, care coordination, and population health management solutions. Tabula Rasa HealthCare Inc has a market cap of 90.57M as of 2022 and a Return on Equity of -316.44%. The company’s products and services are designed to help healthcare organizations improve patient outcomes, reduce hospitalizations, and lower healthcare costs.

    – CeCors Inc ($OTCPK:CEOS)

    CeCors Inc has a market cap of 14.15k as of 2022. The company is engaged in the business of providing environmental consulting and engineering services. It offers services in the areas of air quality, water quality, solid and hazardous waste management, and environmental site assessment and remediation. The company serves clients in the United States and Canada.

    Summary

    Nathan Rich, a Goldman Sachs analyst, has recently re-affirmed his Buy rating for Alignment Healthcare with a price target of $10.00. The healthcare company’s stock closed at this price, indicating a bullish outlook for investors. Rich believes that Alignment Healthcare has excellent potential for growth, and is an attractive investment opportunity. He recommends investors take advantage of the current market conditions and add Alignment Healthcare to their portfolios.

    Rich’s analysis includes looking at the company’s financials, competitive landscape, and growth prospects. With his bullish outlook on Alignment Healthcare, he believes that the stock could reach its target price in the near future.

    Recent Posts

    Leave a Comment